离子通道药物的细胞模型高通量筛选服务

Assay Services

Aurora Biomed provides functional assay services on an exclusive, out-sourced basis. 
We are currently carrying out assay services for various ion channel targets including hERG safety screen. Several options for these services exist, we can read/test flux assay samples from your experiments on ICR, we can screen your compounds/library in our laboratories or we can accept cell lines to develop assay for you as part of our services.

Aurora Biomed has a team of highly trained molecular biologists have a solid understanding of ion channels and flux assays. We enjoy a challenge and feel confident in providing solutions to further your ion channel screening needs.

We are pleased to offer both cold flux assays using our proprietary Ion Channel Reader technology and manual voltage-clamp electrophysiology assays. 

Cold flux assays utilize tracer ions to study the ion channel of interest.  The method of detection for Aurora Biomed’s cold flux assays is flame atomic absorption spectroscopy as employed by our proprietary Ion Channel Reader technology.  The Ion Channel Reader Series provides a high throughput format for ion channel screening by the flux assay approach.  The use of high throughput assays helps reduce the burden on electrophysiology by providing some idea of which compounds should be screened if resources are limited and not all compounds can be screened with manual-patch clamp.  The cold flux assay approach is ideal for determining which compounds to follow up with electrophysiology as there is a strong linear correlation (R=0.88) and consistently identical drug rank orders between the two methods.

Manual voltage-clamp electrophysiology is the gold-standard for ion channel screening.  Moreover, the FDA requires in vitro electrophysiology studies in conjunction with in vivo studies for compounds submitted for NDA status.  Oocyte-based studies assess potential cellular mechanisms that may not be evident from in vivo data.

 ICR 12000

The ICR 12000 designed for ultra high throughput screening of compound libraries against ion channel targets. Based on the robustness of Aurora Biomed's ICR technology, the reader offers high sensitivity generating accurate drug rank order matching electrophysiology data. This new member of the ICR series provides the throughput to access compound QT liability early in the drug discovery process.